Pure Global
NCT06359067

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

A Real-World Study of Bispecific Antibodies, Teclistamab and Elranatamab, for Patients With Multiple Myeloma
Assistance Publique - Hôpitaux de Paris·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Assistance Publique - Hôpitaux de Paris
Location
Paris, France
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2022
End date
Dec 31, 2023
Enrollment
600 participants
Primary outcome

Infection rate

Summary

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for
 patients with multiple myeloma who are refractory to all current drugs. The results are very
 encouraging but complicated adverse events, particularly infectious. This study analyzes
 survival data in patients treated with BsAb, as well as safety data, in particular the
 proportions and locations of infectious events. The results are compared to a control cohort.
 This study is multicentric on all the university hospitals of Paris (AP-HP).

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06359067
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06359067 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Completed. The study focuses on Multiple Myeloma. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.